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The aim of the present study was to investigate the antiatherosclerotic eﬀect of active principle (FIIc) isolated from aqueous fruit
pulp extract of Eugenia jambolana.C r u d ea q u e o u se x t r a c to fE. jambolana was subjected to puriﬁcation using chromatographic
techniques which yielded puriﬁed active compound (FIIc). Purity of FIIc was tested by HPLC. Phytochemical investigation of
FIIc by NMR, IR, and UV spectra showed that the puriﬁed compound is α-hydroxy succinamic acid. The streptozotocin- (STZ-)
induced diabetic rats were fed atherosclerotic (Ath) diet containing 1.5mL olive oil containing 8mg (3, 20,000 IU) vitamin D2 and
40mg cholesterol for 5 consecutive days. The STZ-induced diabetic rats receiving Ath diet were orally administered FIIc at doses
of 10, 15, and 20mg/kg, and results were compared with reference drug, that is, glibenclamide (600μg/mg) and healthy control.
30-day treatment with FIIc resulted in signiﬁcant (P<. 001) improvement in blood glucose, serum lipid proﬁle, apolipoproteins
(Apo A1 and apoB100), and endothelial dysfunction parameters. Histomorphological studies also conﬁrmed biochemical ﬁndings.
Our results showed that FIIc has protective eﬀect on hyperglycemia-induced atherosclerosis.
1.Introduction
Out of a large number of herbal drugs which possess
antidiabetic activity in the Ayurvedic system of medicine
of India, Eugenia jambolana is being widely used to treat
diabetes by the traditional practitioners over many centuries
[1]. It belongs to family Myrtaceae, (called Black plum/Black
berry in English and Jamun in Hindi in India).
The antihyperglycemic activity of seeds of E. jambolana
is well documented [2–11]. Studies on antihyperglycemic
activity of the fruit pulp of E. jambolana are not much
reported.Achrekaretal.,1991[4]ﬁrstclaimedthatthewater
extract of fruit pulp of E. jambolana showed hypoglycemic
activity immediately or as early as 30 minutes, while seeds
required 24 hours for the same eﬀect. Hot water extract of
dried fruit pulp was found to be inactive in alloxan-induced
hyperglycemia [2].Inourpreviousstudies[12],waterextract
of E. jambolana was found to be more potent in reducing
thefastingbloodglucoseincomparisontotheethanolicfruit
pulp extract. However scientiﬁc studies are lacking regarding
antiatheroscleroticactivityofactivecompoundisolatedfrom
fruit pulp of E. jambolana. Survey of literature showed that
traditional medicinal plants having antidiabetic properties
can be used as drugs or simple dietary adjuvant to existing
therapies of diabetes and its associated complications like
atherosclerosis [13–19]. In our lab, active compound (FIIc)
has already been isolated (US Patent no. 6,426,826 dated
6th August 2002; Indian Process Patent no. 1,88,759 May
2003; Indian Product Patent no. 2,30,753 February 2009).
Hence an attempt has been made to investigate the eﬀect
of puriﬁed active principle (FIIc) on hyperglycemia-induced
atherosclerosis.
2.MaterialsandMethods
2.1. Plant Material. Fruits of E. jambolana were procured
from the Azadpur Mandi (Herbal market) at Delhi. The
identity was made with the help of a botanist using taxo-
nomic rules (voucher specimen no. P-96/6) and specimen
is kept for further references in Botanical Garden, Kolkata,
India.2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: HPLC ﬁngerprint of active principle isolated from fruit
pulp of Eugenia jambolana.
2.2. Preparation of Crude Aqueous Extract. Fresh fruits of E.
jambolana were purchased from local market and washed
thoroughly. Seeds were separated from fruit pulp of E.
jambolana. The pulp was ground for 10 minutes in a
mixer with distilled water (500mL). It was allowed to stand
overnight at 4◦C. The pulp was then ﬁltered through 5-6
layers of muslin cloth. The whole procedure was carried out
in cold room at 4◦C. The ﬁltrate was ﬁrst centrifuged for 15
minutes in a refrigerated centrifuge at 10,000rpm at 4◦Ca n d
then lyophilized to store it for a longer duration. The yield of
lyophilized water extract was about 10g from 650g of fruit
pulp, which was obtained from 1kg fruits of E. jambolana.
2.3. Isolation and Puriﬁcation of Active Antihyperglycemic
Compound FIIc. Thelyophilizedaqueousextractofpulpwas
subjected to isolation and puriﬁcation of antihyperglycemic
compound. The puriﬁcation was done by ion exchange
column chromatography using diethylaminoethylcellulose-
52 (DEAE-52) as the column material. Fractions were then
eluted with 0.1M phosphate buﬀer (pH 6.0). The ﬁrst
colourless fraction (FI) showed hyperglycemic activity. Then
after elution of some inactive material, an antihyperglycemic
fraction (FII) was obtained. This was followed by fractions
FIII and FIV. The separation of FII and FIII was clear-
cut without overlapping. As FII was found to have potent
antihyperglycemic activity. It was further subjected to puriﬁ-
cation by rechromatography and active compound FIIc was
obtained (as discussed in the introduction patents have
already been granted for the isolation of active principle).
2.4. Chemical Characterization of Active Antihyperglycemic
Compound FIIc. Homogeneity of FIIc was conﬁrmed by
HPLC which gave a single peak after employing it on
chromolith column (chromolith performance HPLC col-
umn RP-18e 100–4.6mm). FIIc was eluted with mobile
phase (water:methanol:Acetonitrile:: 70:15:15) and mon-
itored by PDA detector at wavelength 220nm (Instrument
Shimadzu HPLC model SPD-M20A). A single peak was
observed in chromatogram, suggesting that FIIc was almost
homogenous (Figure 1).
Puriﬁed antihyperglycemic compound FIIc is soluble in
water and on heating, burns with a nonsmoky ﬂame. Ele-
mental analysis of puriﬁed hypoglycemic compound showed
the presence of carbon, hydrogen, oxygen, and nitrogen
with a ratio of carbon to nitrogen of 4:1, respectively.
One-dimensional IH NMR spectra showed four signals at δ
2.4(dd),2.66(dd),3.66(S),andatδ 4.38(dd).Type 13CNMR
showed ﬁne signals of δ 45.5, 65.3, 73.0, 182.7, and 184.0.
The signals at 182.7 and 184 were described to be carbonyl
containing carbon. IR spectrum showed the presence of
bands at 1656.0 and 1590.2 which conﬁrmed the presence
of amide and acid moiety, respectively.
Detailed UV, NMR, and IR spectrum suggested that the
p u r i ﬁ e da c t i v ec o m p o u n d( F I I c )i sα-hydroxy succinamic
acid, which is a small aliphatic organic compound having
molecular formula C4H7O4N.
2.5. Experimental Animals. Male Wistar albino rats (weigh-
ing 160–200g) were procured from Central Animal House of
University College of Medical Sciences (UCMS), University
of Delhi, Delhi, India. The animals were housed in standard
conditions of temperature (22 ± 2◦C) and at 12h light-dark
cycle. The rats were fed with commercial diet (Hindustan
liver Ltd., Mumbai) and water ad libitum.T h ee x p e r i m e n t a l
protocol was approved by the Institutional Animal Ethical
Committee (IAEC) of UCMS, Delhi, India. All experimental
procedures were conducted in accordance with the ethical
guidelines of International Association for the Study of Pain
[20].
2.6. Experimental Induction of Diabetes. A freshly prepared
solution of streptozotocin (45mg/kg in 0.1M citrate buﬀer,
pH 4.5) was injected intraperitoneally to overnight fasted
rats. Streptozotocin- (STZ-) injected animals exhibited
hyperglycemia within 48hrs [21]. Fasting blood glucose
(FBG) levels were measured after 48 hours and again
repeated twice at an interval of three days. The rats with
stabilized diabetes having FBG values of 250mg/dL or above
were considered diabetic and were included in the study.
2.7. Sample Collection. Blood was drawn from retro-orbital
plexus of overnight fasted rats by using microcapillary tech-
nique [22]. Blood samples were collected in anticoagulant
(sodium ﬂuoride and potassium oxalate) vials for plasma
separation to estimate blood glucose. For estimation of
soluble vascular cell adhesion molecule-1 (sVCAM-1) and
ﬁbrinogen, whole blood was collected in EDTA vial and
separated plasma was used. The blood collected in plain
vials, was allowed to clot for separation of serum. Serum
was used for estimation of serum lipid proﬁle parameters,
oxidized LDL (Ox-LDL), apolipoproteinA1 (ApoA1)a n d
apolipoproteinB100 (ApoB100), and serum total NO levels.
Heart and aorta were excised and preserved in 10% neutral
formalin for histomorphological studies.
2.8. Analytical Methods. Blood glucose was measured using
the glucose oxidase-peroxidase method [23]. The levels
of sVCAM and ﬁbrinogen were estimated by Enzyme
Linked Immuno Sorbant Assay (ELISA) using commercially
available kits from Diaclone France and Hyphen Biomed,
France, respectively. Triglycerides (TG) were measured by
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cholesterol (TC) was assayed as per the method of Allain et
al., 1974 [25]. High-density lipoprotein cholesterol (HDL-
C) was determined by Burstein et al.’s method [26]. Low-
density lipoprotein cholesterol (LDL-C) and very low-
density lipoprotein cholesterol (VLDL-C) were calculated
by using the formula of Friedwald et al. [27]. ApoA1 and
ApoB100 were estimated by immunoturbidimetry method
using commercially available kits from Giesse diagnostics.
NO end products and Ox-LDL were estimated as per the
method of Moshage et al., 1995 [28] and Ahotupa et al., 1996
[29].
2.9. Experimental Design. The experiment was carried out
on following groups of seven rats in each group. Atheroscle-
rotic (Ath) diet includes 1.5mL olive oil containing 8 mg
(3,20,000IU) vitamin D2 and 40mg cholesterol and was
givenfor5consecutivedays.Group1:healthycontrol;Group
2: diabetic control + Ath diet; Group 3: diabetic + Ath
diet + Glibenclamide (600μg/kg); Group 4: diabetic + Ath
diet + FIIc (10mg/kg); Group 5: diabetic + Ath diet + FIIc
(15mg/kg); Group 6: diabetic + Ath diet + FIIc (20mg/kg).
Control rats (groups 1 & 2) received vehicle, that is,
distilled water. Group 3 received the glibenclamide and
groups 4, 5, and 6 received FIIc at the above-mentioned
dose dissolved in 1mL of distilled water. The treatment was
given daily for a period of 30 days using standard orogastric
cannula. Fasting blood glucose levels were measured at 0, 6,
10, 20, and 30 days. All other parameters were determined at
day 0, day 6, and day 30.
2.10. Histomorphological Studies. For histomorphological
studies, heart and aorta were dissected out and washed
thoroughly with physiological saline to remove adherent fats
and blood. Both the tissues were grossly examined. The
sections of heart and aorta were taken for paraﬃn blocks.
Sections were cut at 4-5 microns and stained with routine
haematoxylin and eosin stains. These slides were evaluated
underlightmicroscopeforhistomorphologicalexamination.
2.11. Statistical Analysis. Values are expressed as the mean
± SEM for seven animals in each group. The data was
analyzed by using repeated measure analysis of variance
(ANOVA) followed by Dunnett’s test and repeated measure
ANOVAfollowedbyTukey’stest.Theresultswereconsidered
signiﬁcant at P<. 05.
3. Results
3.1. Glycemic Control. There was dose-dependent fall in the
levels of FBG in diabetic rats treated with FIIc (10, 15, and
20mg/kg) from day 6 to day 30. Untreated diabetic rats
showed marked hyperglycemia throughout the experimental
period(Table 1).AstheFIIcproduceddose-dependantfallin
blood glucose level up to 15mg/kg, this dose was considered
as eﬀective dose and further studies were carried out with
15mg/kg dose of the FIIc. The diabetic rats fed with the FIIc
and glibenclamide exhibited remarkable glycemic control as
evident by signiﬁcant decrease (P<. 001) in FBG.
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Figure 2: Eﬀect of single dose of FIIc (15mg/kg) on fasting
blood glucose at diﬀerent time interval in diabetic rats. Eﬀect
of glibenclamide (600μg/kg) is shown for comparison. The rats
were treated with a single dose of drugs, and FBG were measured
at diﬀerent time points, that is, from 90min to 72hr. In FIIc
treated group, FBG level gradually declined up to 48 hr, whereas in
glibenclamide-treated group, gradual fall in FBG level was observed
only up to 5hr.
As shown in Figure 2, the oral administration of single
dose of FIIc (15mg/kg) exhibited a gradual decline in FBG
level from 90min to 48hr and thereafter rise in FBG was
observed. The antihyperglycemic eﬀect of FIIc (15mg/kg)
was better than that of glibenclamide as shown in Figure 2.
3.2. Lipidemic Control. Diabetic control animals showed sig-
niﬁcant increment (P<. 001) in the levels of TC (Figure 3),
TG (Figure 4), LDL-C (Figure 6) & VLDL-C (Figure 7)a n d
reduction (P<. 001) in HDL-C (Figure 5) compared with
healthy control. Treatment with FIIc for 30 days signiﬁcantly
reduced (P<. 001) the levels of TG, TC, LDL-C, and VLDL-
C.Thesigniﬁcant(P<. 001)improvementwasalsoobserved
in HDL-C after treatment with FIIc. Moreover there was
signiﬁcantimprovementinthelevelsofApoA1,A poB 100,and
ApoB100/ApoA1 ratio (Table 2). The eﬀect produced by FIIc
was better than that of glibenclamide.
3.3. Endothelial Dysfunction Parameters. A signiﬁcant eleva-
tion (P<. 001) in the levels of Ox-LDL (Figure 8), sVCAM-
1( Figure 9) ,a n dﬁ b r i n o g e n( Figure 10)w a so b s e r v e di n
diabetic control rats as compared to normal rats. The Ox-
LDL was also found to be signiﬁcantly decreased (P<. 001)
in FIIc-fed diabetic rats. The supplementation with the FIIc
reverted back the sVCAM-1 and ﬁbrinogen levels to near
normal in diabetic rats, which was statistically signiﬁcant at
P<. 001. Glibenclamide-treated diabetic rats also produced
signiﬁcantreduction(P<. 001)inthelevelsofoxidizedLDL,
sVCAM-1, and ﬁbrinogen.
As shown in Figure 11, the total nitric oxide levels in
diabetic control animals was found to be signiﬁcantly lower4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀect of oral administration of diﬀerent doses of FIIc on fasting blood glucose (mg/dl) at various time intervals
Group Dose Day 0 Day 6 Day 10 Day 20 Day 30
Healthy control — 83.10 ± 4.5 79.50 ± 10.2 84.90 ± 5.0 83.70 ± 7.6 83.50 ± 8.0
Diabetic control — 301.5 ± 17.1 306.3 ± 12.9 313.7 ± 13.9a 322.4 ± 10.3a 326.3 ± 9.8a
Diabetic + Glibenclamide 600μg 302.9 ± 16.4 259.5 ± 39.5a 208.3 ± 21.9a 187.1 ± 23.2a 144.1 ± 17.9a
Diabetic + FIIc 10mg 302.6 ± 13.1 300.9 ± 19.6 276.0 ± 25.4a 213.3 ± 28.3a 187.8 ± 16.8a
Diabetic + FIIc 15mg 306.5 ± 14.9 269.0 ± 31.2a 228.5 ± 26.7a 155.1 ± 27.4a 121.2 ± 16.8a
Diabetic + FIIc 20mg 301.8 ± 12.1 298.1 ± 27.3 259.8 ± 26.2a 195.4 ± 30.2a 132.3 ± 18.6a
Data are expressed as mean ± SEM of ﬁve animals in each group and evaluated by repeated measure ANOVA followed by Dunnett’s test.
aP<. 001 versus day 0.
Table 2: % Change in Apolipoprotein-A1, Apolipoprotein-B100, and Apolipoprotein B100/Apolipoprotein-A1 ratio after 30 days.
Parameters Normal control Diabetic control Diabetic + Ath diet + Glibenclamide Diabetic + Ath diet + FIIc
Apolipoprotein-A1 — 42% ↓ 9.3% ↑ 10.4% ↑
Apolipoprotein-B100 — 10.2% ↑ 16.9% ↓ 21.5% ↓
Apo-B100/A1 ratio — 49.1% ↑ 24.8% ↓ 27.8% ↓
0
50
100
150
200
250
300
S
e
r
u
m
c
h
o
l
e
s
t
e
r
o
l
(
m
g
/
d
L
)
Healthy
control
Diabetic
control
Diabetic + Ath
+g l i b
Diabetic + Ath
+f I I c
Day 0
Day 6
Day 30
b
a, b
a, b
b
a, c
b
a, c
Figure 3: Eﬀect of oral administration of FIIc (15mg/kg) on serum
cholesterol after 30-day treatment. Data are expressed as mean ±
SEM of seven animals in each group. aP<. 001 versus initial values;
bP<. 001 versus normal control; cP<. 001 versus diabetic control.
(P<. 001) than in healthy control group. The protective
eﬀect of FIIc is indicated by the signiﬁcant increase (P<
.001) in levels of total nitric oxide of FIIc-fed diabetic
rats. The eﬀect of glibenclamide on endothelial dysfunction
parameters was noticed at P<. 001 for nitric oxide levels,
serum nitrite, and serum nitrate in diabetic rats. Diabetic
control animals showed signiﬁcantly (P<. 001) lowered
nitric oxide levels when compared with healthy control.
3.4. Histomorphological Studies. Histomorphological exam-
ination of normal healthy control group showed heart and
aorta within normal limits (Figure 12(a)). Histomorpho-
logical examination of tissue from diabetic rats showed
atherosclerotic lesions and large areas of vacuolization and
inﬂammationthatarebothacuteandchronicinﬂammations
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Figure 4: Eﬀect of oral administration of FIIc (15mg/kg) on serum
triglyceride after 30-day treatment. Data are expressed as mean ±
SEM of seven animals in each group. aP<. 001 versus initial values;
bP<. 001 versus normal control; cP<. 001 versus diabetic control.
(Figures 12(b) and 12(c)). The inﬂammation was predom-
inantly by mononuclear cells comprising of lymphocytes,
histocytes, and plasma cells.
After 30-day treatment with FIIc, inﬂammation in
myocardium was reduced as compared to diabetic control.
After 30-day treatment with FIIc, normal histology of heart
was observed in FIIc treated animals (Figures 12(d) and
12(e)).
4. Discussion
Atherogenicity with subsequent cardiovascular manifesta-
tions is one of the important causes of high mortality
and morbidity. Various agents which aﬀect hyperlipidemia
are still not used for prevention of atherosclerosis, becauseEvidence-Based Complementary and Alternative Medicine 5
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Figure 5: Eﬀect of oral administration of FIIc (15mg/kg) on HDL-
C after 30-day treatment. Data are expressed as mean ± SEM of
seven animals in each group. aP<. 001 versus initial values; bP<
.001 versus normal control; cP<. 001 versus diabetic control.
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Figure 6:EﬀectoforaladministrationofFIIc(15mg/kg)onLDL-C
after 30-day treatment. Data are expressed as mean ± SEM of seven
animals in each group. aP<. 001 versus initial values; bP<. 001
versus normal control; cP<. 001 versus diabetic control.
of their potential toxicity and intolerance [30]. Antihyper-
glycemic eﬀect of aqueous extract of E. jambolana fruit pulp
in normal and alloxan-induced (80mg/kg) diabetic rabbits
have already been shown in our previous study [12]. The
main goal of the present study was to purify active principle
from aqueous fruit pulp extract and ﬁnd its eﬃcacy against
diet-induced atherosclerosis in diabetic rats.
In the present study, we observed that the antihyper-
glycemic eﬀect of FIIc starts to come from 90min and
gradually increases (Figure 2). In separate groups of animals,
it was found that fall in FBG steadily occurs up to 48hr
with a single dose of 15mg/kg, and thereafter increases in
diabetic rats. This also showed that the antihyperglycemic
eﬀectofFIIc persiststill48hr withits single dose (15mg/kg),
which was not observed in glibenclamide-treated rats. After
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Figure 7:EﬀectoforaladministrationofFIIc(15mg/kg)onVLDL-
C after 30-day treatment. Data are expressed as mean ± SEM of
seven animals in each group. aP<. 001 versus initial values; bP<
.001 versus normal control; cP<. 001 versus diabetic control.
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Figure 8: Eﬀect of oral administration of FIIc (15mg/kg) on Ox-
LDL after 30-day treatment. Data are expressed as mean ± SEM of
seven animals in each group. aP<. 001 versus initial values; bP<
.001 versus normal control; cP<. 001 versus diabetic control.
30-day treatment, the FIIc like glibenclamide produced
signiﬁcant reduction in blood glucose level of STZ-induced
diabetic rats. Capacity of FIIc to signiﬁcantly bringing
down the elevated levels of blood glucose in diabetic rats
shows its antihyperglycemic activity, which is an essential
trigger for the development of normal homeostasis during
experimentaldiabetesanditsassociatedcomplications.Since
hyperlipidemia is one of the major risk factors for the
development of atherosclerosis. The increased TG and TC
levels and decreased HDL-C are known risk factors for
coronary heart disease (CHD) [31, 32]. Lipids and apopro-
tein moieties of LDL particle may be damaged in reaction
with free radicals (oxidized LDL). Increased postsynthetic
chemical modiﬁcation of LDL by oxidation, glycosylation,
or both may induce endothelial injury and/or accelerate6 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Eﬀect of oral administration of FIIc (15mg/kg) on
sVCAM-1 after 30-day treatment. Data are expressed as mean ±
SEM of seven animals in each group. aP<. 001 versus initial values;
bP<. 001 versus normal control; cP<. 001 versus diabetic control.
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Figure 10: Eﬀect of oral administration of FIIc (15mg/kg) on
Fibrinogen levels after 30-day treatment. Data are expressed as
mean ±SEMofsevenanimalsineachgroup. aP<. 001versusinitial
values; bP<. 001 versus normal control; cP<. 001 versus diabetic
control.
foam cell formation by monocyte macrophage in arterial
intima [33]. Plasma ApoB100 concentration reﬂects the
number of atherogenic lipoproteins and studies done so far
demonstrated that ApoB100 can be a valuable predictor for
coronary artery disease (CAD) [34, 35]. Recent studies have
shown that the ApoB100/ApoA1 ratio is strongly associated
with risk of CAD [36]. The altered lipid and lipoprotein
proﬁle, that is, increase in TG, TC and LDL-C with fall
in HDL-C was reversed towards normal level along with
signiﬁcant improvement in Ox-LDL, ApoA1,A p o B 100 and
ApoB100/ApoA1 ratio after administration of the FIIc for
30 days. As these factors showed signiﬁcant improvement
following treatment with the FIIc, it may be suggested that
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Figure 11: Eﬀect of oral administration of FIIc (15mg/kg) on Total
Nolevelsafter30-daytreatment.Dataareexpressedasmean ±SEM
of seven animals in each group. aP<. 001 versus initial values; bP<
.001 versus normal control; cP<. 001 versus diabetic control.
the FIIc may help to prevent the progression of cardi-
ovascular diseases.
Endothelial dysfunction with its proinﬂammatory and
prothrombotic phenotype is a key element in the patho-
genesis of atherosclerosis in humans [37]. Abnormalities of
NO/O2 pathway occur in diabetes and are important cause
of endothelial dysfunction. Serum total NO levels (nitrite
+ nitrate) were found to be decreased in type 2 diabetic
subjects [38]. In the present study, which is in accordance
with various previous studies, serum total NO levels were
signiﬁcantly (P<. 001) decreased in diabetic control rats and
treatment with FIIc signiﬁcantly (P<. 001) improved the
total NO levels. VCAM-1 is a transmembrane glycoprotein,
whichisamemberoftheimmunoglobulin genesuperfamily.
These molecules play an important role in adhesion of
circulating leukocytes to endothelium, which is the ﬁrst
step in initiation of atherosclerosis [38]. The pathogenic
mechanism (s) whereby ﬁbrinogen acts as a cardiovascular
risk factor is likely to be multifactorial. Plasma ﬁbrinogen
levels are associated with platelet aggregability [39]w h i c h
is important in the genesis of a vascular lesion [40]. In the
present study, circulating levels of sVCAM-1 and ﬁbrinogen
were signiﬁcantly high in diabetic control rats compared
to healthy control (P<. 001) and treatment with FIIc
signiﬁcantly improved the circulating levels of sVCAM-1 as
well as ﬁbrinogen.
The antihyperglycemic and dyslipidemic eﬀect of FIIc
was comparable to that of glibenclamide. However, the
eﬀect of the FIIc on endothelial dysfunction parameters
was found to be better than that of glibenclamide. In con-
clusion, the FIIc exhibited potential antihyperglycemic and
antiatherosclerotic activity in diabetic animals. The results
of the present study provides impetus for further molecular
and mechanistic studies on the therapeutic action of FIIc,
before it can be administered as possible adjuvant therapy
for reducing atherosclerotic complications in diabetes.Evidence-Based Complementary and Alternative Medicine 7
(a) (b) (c)
(d) (e)
Figure 12: (a) Histomorphological study of healthy rats heart showing normal morphology (haematoxylin and eosin (H-E) stain, original
magniﬁcation 20x). (b) Diabetic control rats (H-E stain, original magniﬁcation 20x) showing atherosclerotic plaque. (c) Diabetic control
rats (H-E stain, original magniﬁcation 20x) showing large areas of inﬂammation. (d) Diabetic rats treated with active principle FIIc isolated
from Eugenia jambolana fruit pulp (H-E stain, original magniﬁcation 20x) showing morphology of heart chamber within normal limits. (e)
Diabetic rats treated with FIIc (H-E stain, original magniﬁcation 20x) showing lesser inﬂammation.
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Extraction and puriﬁcation
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Figure 13: Therapeutic approach of FIIc puriﬁed from fruit pulp of Eugenia jambolana on experimental-induced atherosclerosis.8 Evidence-Based Complementary and Alternative Medicine
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